CAT and Parkinson disease: The IN administration of C-LipSel-siSNCA2 led to a marked improvement in motor and non-motor function, and a substantial restoration of dopamine levels and catalase activity as well as reducing MAO-B levels, indicating its potential for mitigating PD symptoms.